Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype.

Histopathology - 1 Dec 2023

Huvila Jutta, Thompson Emily F, Vanden Broek Jamie, Lum Amy, Senz Janine, Leung Samuel, Gilks C Blake, Köbel Martin, McAlpine Jessica N, Jamieson Amy

Abstract excerpt

AIMS: The significance of subclonal expression of p53 (abrupt transition from wild-type to mutant-pattern staining) is not well understood, and the arbitrary diagnostic cut-off of 10% between NSMP and p53abn molecular subtypes of endometrial carcinoma (EC) has not been critically assessed. Our aim was to characterise subclonal p53 and discrepant p53 expression/TP53 sequencing results in EC and assess their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Relevance
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 37580913
DOI: 10.1111/his.15029

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype.PMID 37580913Read ↗

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.Semantic proximity Read ↗

p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.Semantic proximity Read ↗

Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.Semantic proximity Read ↗

Incorporation of molecular characteristics into endometrial cancer management.Semantic proximity Read ↗

The emerging role of molecular pathology in directing the systemic treatment of endometrial cancerSemantic proximity Read ↗

Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments.Semantic proximity Read ↗

Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.Semantic proximity Read ↗

Interpretation strategy of POLE, mismatch repair deficiency, and p53 in the multiple molecular classification of endometrial carcinoma and its clinical differences from single classification: a retrospective cohort study.Semantic proximity Read ↗

Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.Semantic proximity Read ↗

Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification.Semantic proximity Read ↗

Incorporating Molecular Classification When Stratifying the Survival Risk of Patients with High-Grade Endometrial CarcinomasSemantic proximity Read ↗

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.